This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Clinical Insider
Clinical Insider

Acrometa wins Gov support to build lab for “global” CRO in Singapore

Posted by on 04 January 2023
Share this article

Acrometa has won Singaporean government support to build a facility for an unnamed “global” clinical research organization (CRO).

According to a statement issued to the Singapore Stock Exchange, the investment received a letter of award (LOA) in which the government promised to provide S$6.1 million to support the design and construction of laboratory and office space for the CRO.

In a press statement Arcometa executive chairman Lim Say Chin said “we are greatly encouraged that the Project involves a new customer in the biotechnology space. This speaks of the confidence that our customers have in our capabilities.

Chin added, “we will continue to work hard towards delivering quality services, leveraging on our established track record and proven expertise as controlled environment specialist engineers.”

Acrometa – which used to operate as ACROMEC Limited - is a specialist engineering services provider with more than 25 years of experience in the field of controlled environments.

The croup claims expertise in the design and construction of facilities requiring controlled environments such as laboratories, medical and sterile facilities, and cleanrooms.

Acrometa has not disclosed for which global clinical research organization it will build the new laboratory and office facility. It did disclose that site work will begin soon and that “a binding contract would be executed in due course”

The firm also said, “the project is expected to contribute positively to the earnings per share and net tangible assets per share of the Group for the current financial year ending 30 September 2023.”

According to data from Singapore’s Health Sciences Authority (HAS) some 146 clinical trials were approved in the country in 2021, which is down from the 156 given the green light the year before.
The majority of the studies approved in 2021 focused on therapies for the treatment of cancer.


Share this article

Sign up for Clinical Insider email updates